查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1627626

全球免疫抑制剂市场：预测（2025-2030）

Global Immunosuppressant Drugs Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球免疫抑制剂市场规模预计将以12.42%的复合年增长率成长，从2025年的427.21亿美元增至2030年的767.19亿美元。

免疫抑制剂在临床上可用于治疗皮肤病、多发性硬化症和类风湿性关节炎等自体免疫疾病。这些药物也称为抗排斥药物，可防止移植器官出现排斥反应。帮助患有慢性疾病的人，特别是那些需要器官移植的人的需要，以及增强移植过程的技术进步可能会显着促进市场成长。

根据世界卫生组织 (WHO) 2023 年 9 月的报告，非传染性疾病 (NCD) 每年导致约 4,100 万人死亡，约占全球死亡人数的 74%。这些疾病包括呼吸系统疾病、癌症、肾臟疾病和心血管疾病。免疫抑制剂的开发和器官移植的进步预计将减少这些疾病造成的死亡并扩大市场。

免疫抑制剂市场的驱动因素

  • 慢性病的增加促进了免疫抑制剂市场的成长

由于急性白血病、难治性贫血和骨质疏鬆症，对干细胞移植的需求不断增加，而导致肾臟移植的慢性肾臟病也在增加。因此，器官移植的负担导致免疫抑制药物的需求大幅上升，进一步拉动全球市场。临床试验的扩大、併购的增加以及支持药物发现和药物开发的CDMO和CRO的快速成长也是推动市场扩张的因素。

免疫抑制剂市场的地理前景

  • 预计北美在预测期内将出现显着成长

技术进步和市场参与企业的存在正在推动该区域市场的发展。在美国和加拿大等国家，器官移植和相关手术的需求不断增加，免疫抑制剂的需求不断增加，支持了市场的扩张。大众对器官捐赠的认识不断提高，也为更多的移植手术打开了大门，并可能在未来五年加速免疫抑制剂市场的成长。在美国，90%的成年人支持器官捐赠。由于该地区自体免疫疾病盛行率上升以及研发成本上升，免疫抑制剂市场正在扩大。

为什么要购买这份报告？

  • 富有洞察力的分析：获得涵盖关键和新兴地区的深入市场洞察，重点关注客户细分、政府政策和社会经济因素、消费者偏好、行业和其他子区隔。
  • 竞争格局：了解世界主要企业采取的策略策略，并了解透过正确的策略渗透市场的潜力。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中发现新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问、中小企业和大型企业有用且具有成本效益。

它有什么用？

产业与市场考量、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范与影响、新产品开发、竞争影响

调查范围

  • 2022年至2030年的实际资料和预测
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争定位、策略和市场占有率分析
  • 区域收益成长和预测分析，包括细分市场和国家
  • 公司简介（主要是策略、产品、财务资讯、主要动态等）

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现
  • CXO观点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球免疫抑制剂市场：依药物类别

  • 介绍
  • Calcineurin抑制剂
  • mTOR抑制剂
  • 抗体
  • 其他的

第六章全球免疫抑制剂市场：依应用分类

  • 介绍
  • 器官移植
  • 自体免疫疾病

第七章全球免疫抑制剂市场：依通路分类

  • 介绍
  • 在线的
  • 离线

第八章全球免疫抑制剂市场：按地区

  • 介绍
  • 北美洲
    • 按药品类别
    • 按用途
    • 按分销管道
    • 按国家/地区
  • 南美洲
    • 按药品类别
    • 按用途
    • 按分销管道
    • 按国家/地区
  • 欧洲
    • 按药品类别
    • 按用途
    • 按分销管道
    • 按国家/地区
  • 中东/非洲
    • 按药品类别
    • 按用途
    • 按分销管道
    • 按国家/地区
  • 亚太地区
    • 按药品类别
    • 按用途
    • 按分销管道
    • 按国家/地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 併购/协议/合作
  • 竞争对手仪表板

第十章 公司简介

  • Astellas Pharma Inc.
  • Sanofi
  • AbbVie Inc.
  • Veloxis Pharmaceuticals Inc.
  • GlaxoSmithKline plc
  • Dr. Reddy's Laboratories Ltd.
  • Lupin
  • Neovii
  • F. Hoffmann-La Roche Ltd
  • Biocon
  • Novartis
  • Pfizer
  • Veloxis
简介目录
Product Code: KSI061613971

The global Immunosuppressant Drugs market is expected to grow at a CAGR of 12.42%, reaching a market size of US$76.719 billion in 2030 from US$42.721 billion in 2025.

Immunosuppressive drugs find their clinical utility in managing autoimmune diseases such as skin disorders, multiple sclerosis, and rheumatoid arthritis. These medications, which are also known as anti-rejection medications, prevent our body from rejecting transplanted organs. The need to support populations with chronic ailments, particularly those requiring organ transplants and technological advancements that enhance the transplant process, would significantly increase market growth.

According to the World Health Organization report in September 2023, about 41 million die per year from noncommunicable diseases (NCDs), which equals about 74% of all deaths in the world. It would cover respiratory, cancer, kidney, cardiovascular diseases, etc. Improving immunosuppressive medications and the development of organ transplantation would hence reduce some of the mortalities caused by these diseases and boost market expansion.

Global Immunosuppressant Drugs Market Drivers

  • Rising chronic health diseases are contributing to the global Immunosuppressant Drugs market growth

Stem cell transplant requirements are rising for acute leukemia, refractory anemia, and osteopetrosis, while there is an increase in chronic renal diseases that cause kidney transplants. The organ transplant burden has thus led to a colossal rise in the demand for immunosuppressants and has further contributed to the global market. Increasing clinical trials, growing mergers and acquisitions, and the fast-growing CDMOs and CROs supporting drug discovery and development are additional factors fostering market expansion.

Global Immunosuppressant Drugs Market Geographical Outlook

  • North America is witnessing exponential growth during the forecast period.

Technological advancements and the presence of significant market participants aid the development of this regional market. In nations like the US and Canada, rising demand for organ transplants and related procedures increases demand for immunosuppressive medications, propelling market expansion. Growing public awareness of organ donation is also opening the door for more transplant procedures, which will accelerate the immunosuppressive medication market's growth over the next five years. In the United States, 90% of adults favor organ donation. The market for immunosuppressive medications is expanding due to the region's increasing prevalence of autoimmune disease and R&D spending.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The global Immunosuppressant Drugs market is segmented and analyzed as follows:

By Drug Class

  • Calcineurin Inhibitors
  • mTOR inhibitor
  • Antibodies
  • Others

By Application

  • Organ Transplantation
  • Autoimmune Disorder

By Distribution Channel

  • Online
  • Offline

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET BY DRUG CLASS

  • 5.1. Introduction
  • 5.2. Calcineurin Inhibitors
  • 5.3. mTOR inhibitor
  • 5.4. Antibodies
  • 5.5. Others

6. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Organ Transplantation
  • 6.3. Autoimmune Disorder

7. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Online
  • 7.3. Offline

8. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Drug Class
    • 8.2.2. By Application
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Drug Class
    • 8.3.2. By Application
    • 8.3.3. By Distribution Channel
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Drug Class
    • 8.4.2. By Application
    • 8.4.3. By Distribution Channel
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Italy
      • 8.4.4.5. Spain
      • 8.4.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Drug Class
    • 8.5.2. By Application
    • 8.5.3. By Distribution Channel
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Drug Class
    • 8.6.2. By Application
    • 8.6.3. By Distribution Channel
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Taiwan
      • 8.6.4.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Astellas Pharma Inc.
  • 10.2. Sanofi
  • 10.3. AbbVie Inc.
  • 10.4. Veloxis Pharmaceuticals Inc.
  • 10.5. GlaxoSmithKline plc
  • 10.6. Dr. Reddy's Laboratories Ltd.
  • 10.7. Lupin
  • 10.8. Neovii
  • 10.9. F. Hoffmann-La Roche Ltd
  • 10.10. Biocon
  • 10.11. Novartis
  • 10.12. Pfizer
  • 10.13. Veloxis